Risk factors of follicular lymphoma

Bibliography

• Howlader N, Noone AM, Krapcho M, SEER Cancer Statistics Review, 1975 – 2008. National Cancer Institute; Bethesda, MD; 2010. SEER data submission
   Google Scholar
• Ekstrom-Smedby K. Epidemiology and etiology of Non-Hodgkin lymphoma: a review. Acta Oncol 2006;45:258-71
   PubMed Web of Science ®Google Scholar
• Jaffe ES, Harris NL, Stain H, World Health Organization of classification of tumors. Tumors of haematopoietic and lymphoid tissues, IRAC Lyon; 2001
   Google Scholar
• Turner JJ, Hughes AM, Kricker A, WHO Non-Hodgkin's Lymphoma classification by criterion-based report review followed by targeted pathology review an effective strategy for epidemiology studies. Cancer Epidemiol Biomarkers Prev 2005;14:2213-19
   PubMed Web of Science ®Google Scholar
• Freedman A. Follicular lymphoma: 2011 update on diagnosis and management. Am J Hematol 2011;86:768-75
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay S, Readling J, Cotter PD, Transformation of follicular lymphoma to Burkitt-like lymphoma within a single lymph node. Hum Pathol 2005;36:571-5
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Cahu X, Cartron G. Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful? Int J Hematol 2010;92:246-54
   PubMed Web of Science ®Google Scholar
• Zhang Y, Dai Y, Zheng T, Risk factors of Non-Hodgkin Lymphoma. Expert Opin Med Diagn 2011;5:539-50
   PubMedGoogle Scholar
• Wang SS, Nieters A. Unraveling the interactions between environmental factors and genetic polymorphisms in non-Hodgkin lymphoma risk. Expert Rev Anticancer Ther 2010;10:403-13
   PubMed Web of Science ®Google Scholar
• Wang SS, Slager SL, Brennan P, Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10,211 cases and 11,905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007;109:3479-88
   PubMed Web of Science ®Google Scholar
• Hartge P, Wang SS, Bracci PM., Non-hodgkin lymphoma. In: Schottenfeld D, Fraumeni JFJ, editors. Cancer Epidemiology and Prevention. Oxford University Press; New York: 2006. p. 898-918
   Google Scholar
• Roulland S, Lebailly P, Leclues Y, Characterization of the t(14;18) BCL2-IGH translocation in farmers occupationally exposure to pesticides. Cancer Res 2004;64:2264-9
   PubMed Web of Science ®Google Scholar
• Zhang Y, Sanjose SD, Bracci PM, Personal use of hair dye and the risk of certain subtypes of non-Hodgkin lymphoma. Am J Epidemiol 2008;167:1321-31
   PubMed Web of Science ®Google Scholar
• Talamini R, Polesel J, Montella M, Smoking and non-Hodgkin's lymphoma: case-control study in Italy. Int J Cancer 2005;115:606-10
   PubMed Web of Science ®Google Scholar
• Morton LM, Zheng T, Holford TR, Alcohol consumption and risk of non-Hodgkin lymphoma: a pooled analysis. Lancet Oncol 2005;6(7):469-76
   PubMed Web of Science ®Google Scholar
• Troy JD, Hartge P, Weissfeld JL, Associations between anthropometry, cigarette smoking, alcohol consumption, and non-Hodgkin lymphoma in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Epidemiol 2010;171:1270-81
   PubMed Web of Science ®Google Scholar
• Chang ET, Clarke CA, Canchola AJ, Alcohol consumption over time and risk of lymphoid malignancies in the California Teachers Study cohort. Am J Epidemiol 2010;172:1373-83
   PubMed Web of Science ®Google Scholar
• Pylypchuk RD, Schouten LJ, Goldbohm RA, Body mass index, height, and risk of lymphatic malignancies: a prospective cohort study. Am J Epidemiol 2009;170:297-307
   PubMed Web of Science ®Google Scholar
• Cerhan JR, Janney CA, Vachon CM, Anthropometric characteristics, physical activity, and risk of non-Hodgkin's lymphoma subtypes and B-cell chronic lymphocytic leukemia: a prospective study. Am J Epidemiol 2002;156:527-35
   PubMed Web of Science ®Google Scholar
• Skibola CF, Holly EA, Forrest MS, Body mass index, leptin and leptin receptor polymorphisms, and non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 2004;13:779-86
   PubMed Web of Science ®Google Scholar
• Cheng ET, Hjalgrim H, Smedby KE, Body mass index and risk of malignant lymphoma in Scandinavian men and women. JNCI 2005;97:210-18
   PubMed Web of Science ®Google Scholar
• Lan Q, Zheng T, Chanock S, Genetic variants in caspase genes and susceptibility to non-Hodgkin lymphoma. Carcinogenesis 2007;28:823-7
   PubMed Web of Science ®Google Scholar
• Lan Q, Zheng T, Shen M, Genetic polymorphisms in the oxidative stress pathway and susceptibility to non-Hodgkin lymphoma. Hum Genet 2007;121:161-8
   PubMed Web of Science ®Google Scholar
• Rothman N, Skibola CF, Wang SS, Genetic variation in tnf and il10 and risk of non-Hodgkin lymphoma: a report from the Interlymph consortium. Lancet Oncol 2006;7:27-38
   PubMed Web of Science ®Google Scholar
• Bende RJ, Smit LA, van Noesel CJM. Molecular pathways in follicular lymphoma. Leukemia 2007;21:18-29
   PubMed Web of Science ®Google Scholar
• Dunphy CH. Gene expression profiling data in lymphoma and leukemia: review of the literature and extrapolation of pertinent clinical applications. Arch Pathol Lab Med 2006;130:483-520
   PubMed Web of Science ®Google Scholar
• Husson H, Carideo EG, Neuberg D, Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays. Blood 2002;99:282-9
   PubMed Web of Science ®Google Scholar
• Conde L, Halperion E, Akers NK, Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet 2010;42:661-4
   PubMed Web of Science ®Google Scholar
• Smedby KE, Foo JN, Skibola CF, GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma. PLoS Genet 2011;7:e1001378
   PubMed Web of Science ®Google Scholar
• Hayslip J, Montero A. Tumor suppressor gene methylation in follicular lymphoma: a comprehensive review. Mol Cancer 2006;5:44
   PubMed Web of Science ®Google Scholar
• McDonald HL, Gascoyne RD, Horsman D, Involvement of the X chromosome in non-Hodgkin lymphoma. Genes Chromosomes Cancer 2000;28(3):246-57
   PubMed Web of Science ®Google Scholar
• Yang H, Chen CM, Yan P, The androgen receptor gene is preferentially hypermethylated in follicular non-Hodgkin's Lymphomas. Clin Cancer Res 2003;9(11):4034-42
   PubMed Web of Science ®Google Scholar
• Koyama M, Oka T, Ouchida M, Activated proliferation of B-cell lymphomas/leukemias with the SHP1 gene silencing by aberrant CpG methylation. Lab Invest 2003;83(12):1849-58
   PubMed Web of Science ®Google Scholar
• Rossi D, Capello D, Gloghini A, Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia. Haematologica 2004;89(2):154-64
   PubMed Web of Science ®Google Scholar
• Nakatsuka S, Takakuwa T, Tomita Y, Hypermethylation of death-associated protein (DAP) kinase CpG island is frequent not only in B-cell but also in T- and natural killer (NK)/T-cell malignancies. Cancer Sci 2003;94(1):87-91
   PubMed Web of Science ®Google Scholar
• Stranks G, Height SE, Mitchell P, Deletions and rearrangement of CDKN2 in lymphoid malignancy. Blood 1995;85(4):893-901
   PubMed Web of Science ®Google Scholar
• Pinyol M, Cobo F, Bea S, p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood 1998;91(8):2977-84
   PubMed Web of Science ®Google Scholar
• Baur AS, Shaw P, Burri N, Frequent methylation silencing of p15(INK4b) (MTS2) and p16(INK4a) (MTS1) in B-cell and T-cell lymphomas. Blood 1999;94(5):1773-81
   PubMed Web of Science ®Google Scholar
• Martinez-Delgado B, Robledo M, Arranz E, Hypermethylation of p15/ink4b/MTS2 gene is differentially implicated among non-Hodgkin's lymphomas. Leukemia 1998;12(6):937-41
   PubMed Web of Science ®Google Scholar
• Li Y, Nagai H, Ohno T, Aberrant DNA methylation of p57(KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype. Blood 2002;100(7):2572-7
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P, Follicular lymphoma international prognostic index. Blood 2004;104:1258-65
   PubMed Web of Science ®Google Scholar
• Luminari S, Cox MC, Montanini A, Prognostic tools in follicular lymphomas. Expert Rev Hematol 2009;2:549-62
   PubMed Web of Science ®Google Scholar
• Federico M, Bellei M, Marcheselli L, Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project. JNCI 2009;27:4555-62
   Google Scholar
• Arcaini L, Merli M, Passamonti F, Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients. Br J Haemotol 2010;149:455-7
   PubMed Web of Science ®Google Scholar
• Geyer SM, Morton LM, Habermann TM, Smoking, alcohol use, obesity, and overall survival from non-Hodgkin lymphoma: a population-based study. Cancer 2010;116:2993-3000
   PubMed Web of Science ®Google Scholar
• Han X, Zheng T, Foss F, Vegetable and fruit intake and non-Hodgkin lymphoma survival in Connecticut women. Leuk Lymphoma 2010;51:1047-54
   PubMed Web of Science ®Google Scholar
• Thompson CA, Cerhan JR. Fruit and vegetable intake and survival from non-Hodgkin lymphoma: does an apple a day keep the doctor away? Leuk Lymphoma 2010;51:963-4
   PubMed Web of Science ®Google Scholar
• Janikova A, Bolcak K, Pavlik T, Value of [18F] fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: the end of a dilemma? Clin Lymphoma Myeloma 2008;8:287-93
   PubMedGoogle Scholar
• Dave SS, Wright G, Tan B, Prediction of survival in follicular lymphoma based on molecular features of tumor0infiltrating immune cells. NEJM 2004;351:2159-69
   PubMed Web of Science ®Google Scholar
• Tibshirani R. Immune signatures in follicular lymphoma. NEJM 2005;352:1496-7. Comment on NEJM 2004; 351: 2159-69
   PubMed Web of Science ®Google Scholar
• Glas AM, Kersten J, Delahaye LJML, Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 2005;105:301-7
   PubMed Web of Science ®Google Scholar
• Lossos IS, Alizadeh AA, Diehn M, Transformation of follicular lymphoma into diffuse large cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. PNAS 2002;99:8886-91
   PubMed Web of Science ®Google Scholar
• De Vos S, Hofmann WK, Grogan TM, Gene expression profile of serial samples of transformed B-cell lymphomas. Lab Invest 2003;83:271-85
   PubMed Web of Science ®Google Scholar
• Elenitoba-Johnson KS, Jenson SD, Abbott RT, Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy. PNAS 2003;100:7259-64
   PubMed Web of Science ®Google Scholar
• Janikova A, Tichy B, Supikova J, Gene expression profiling in follicular lymphoma and its implication for clinical practice. Leuk Lymphoma 2011;52:59-68
   PubMed Web of Science ®Google Scholar
• Cerhan JR, Wang SS, Maurer MJ, Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood 2007;1009:5439-46
   Google Scholar
• Wrench D, Leighton P, Skibola CF, SNP rs6457327 in the HLA region on chromosome 6p is predictive of the transformation of follicular lymphoma. Blood 2011;117:3147-50
   PubMed Web of Science ®Google Scholar
• Han X, Li Y, Zhang Y, Identification of predictive pathways for non-Hodgkin lymphoma prognosis. Cancer Inform 2010;9:281-92
   PubMedGoogle Scholar
• Ma S, Zhang Y, Huang J, Identification of non-Hodgkin's lymphoma prognosis signatures using the CTGDR method. Bioinformatics 2010;26:15-21
   PubMed Web of Science ®Google Scholar
• Cheung KJJ, Johnson NA, Affleck JG, Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis. Cancer Res 2010;70:9166-74
   PubMed Web of Science ®Google Scholar
• O'Shea D, O'Riain C, Gupta M, Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. Blood 2009;113:2298-301
   PubMed Web of Science ®Google Scholar
• O'Riain C, O'Shea DM, Yang Y, Array-based DNA methylation profiling in follicular lymphoma. Leukemia 2009;23:1858-66
   Google Scholar
• Ferrero S, Drandi D, Mantoan B, Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms. Hematol Oncol 2011;4:167-76
   Google Scholar
• Rambaldi A, Lazzari M, Manzoni C, Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 2002;99:856-62
   PubMed Web of Science ®Google Scholar
• Zipf TF, Johnston DA. Leukemia and Lymphoma: Detection of Minimal Residual Disease. Humana Press; 2002
   Google Scholar
• Evens AM, Winter JN. Update on approaches to the treatment of follicular lymphoma. Clin Oncol News Spec Ed 2011;6:20-30
   Google Scholar
• Ardeshna KM, Smith P, Norton A, Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003;362:516-22
   PubMed Web of Science ®Google Scholar
• Ardeshna KM, Smith P, Qian W, An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2, and 3a). A preliminary analysis. Blood 2010;116; abstract 6
   Web of Science ®Google Scholar
• Cheson BD. New agents in follicular lymphoma. Best Pract Res Clin Haematol 2011;24:305-12
   PubMed Web of Science ®Google Scholar
• Hitz F, Ketterer N, Lohri A, Diagnosis and treatment of follicular lymphoma. Swiss Med Wkly 2011;141:w13247
   PubMed Web of Science ®Google Scholar
• Johnson NA, Gascoyne RD. Gene expression signatures in follicular lymphoma: are they ready for the clinic? Haematologica 2008;93:982-7
   PubMed Web of Science ®Google Scholar